{"id":"NCT00355082","sponsor":"GlaxoSmithKline","briefTitle":"Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy","officialTitle":"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2006-07-21","resultsPosted":"2009-11-25","lastUpdate":"2017-01-02"},"enrollment":226,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy, Partial"],"interventions":[{"type":"DRUG","name":"lamotrigine, 300 mg/day","otherNames":["lamotrigine"]},{"type":"DRUG","name":"lamotrigine, 250 mg/day","otherNames":[]}],"arms":[{"label":"lamotrigine 300","type":"EXPERIMENTAL"},{"label":"lamotrigine 250","type":"EXPERIMENTAL"}],"summary":"This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.","primaryOutcome":{"measure":"The Percentage of Participants in the 300 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)","timeFrame":"From Study Visit 5 through Visit 9 of the Treatment Phase (approximately Week 7 through Week 23)","effectByArm":[{"arm":"Lamotrigine Extended-release (LTG XR), 300 mg","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":103,"countries":["United States","Argentina","Chile","Costa Rica","Puerto Rico","Russia","South Korea","Ukraine"]},"refs":{"pmids":["22497754","22139591"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":112},"commonTop":["Headache","Dizziness","Nasalpharyngitis","Nausea","Somnolence"]}}